Racura Oncology
Company
Racura Oncology develops one asset, in phase 1 (RC220 in egfr-mutant non-small cell lung cancer). Mostly other.
- 1
- Asset
- Furthest stage
- Phase 1
- 2
- Trials
- 1
- Signal
Pipeline
1Phase 1, Other, egfr-mutant non-small cell lung cancer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Trials2
- Signals1